WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting

SHANGHAI, Nov. 6, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 6, 2012.

At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong (Jeff) Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:




WuXi PharmaTech (Cayman) Inc.


Ronald Aldridge (for investors)


Director of Investor Relations


Tel: +1-201-585-2048


Email: [email protected]




Aaron Shi (for the media)


WuXi PharmaTech (Cayman) Inc.


Tel: +86-21-5046-4362


Email: [email protected]


 

SOURCE WuXi PharmaTech (Cayman) Inc.

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.